Clinical Trials
20 trialsNCT03449108 2026-05-22
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03799445 2026-04-30
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02812524 2026-04-24
Ipilimumab for Head and Neck Cancer Patients
Providence Health & Services
Phase 1 Active not recruiting
NCT04080804 2026-04-22
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
University of Pittsburgh
Phase 2 Active not recruiting
NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02919683 2026-01-28
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04326257 2026-01-08
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
University of Pittsburgh
Phase 2 Completed
NCT03172624 2025-12-18
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT03690986 2025-07-23
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Emory University
Phase 1 Recruiting
NCT03246958 2025-06-19
Nivolumab Plus Ipilimumab in Thyroid Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03406247 2025-05-08
ADJORL1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT03162731 2025-04-29
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03146650 2024-01-18
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Northwestern University
Phase 2 Unknown
NCT03749460 2023-12-29
Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers
University of Washington
Phase 1/2 Completed
NCT03003637 2023-10-23
IMCISION
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03097939 2023-10-11
Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma
National Cancer Centre, Singapore
Phase 2 Unknown
NCT03700905 2023-05-23
IMSTAR-HN
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Unknown
NCT03620123 2022-11-18
OPTIM
AIO-Studien-gGmbH
Phase 2 Completed